Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Seminars In Cancer Biology 2017, 52: 103-109. PMID: 29183778, PMCID: PMC5970946, DOI: 10.1016/j.semcancer.2017.11.019.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaCell lung carcinomaLung cancerWorld Health OrganizationLung carcinomaSignificant prognostic impactLung cancer patientsRecent large-scale genomic studiesSmall biopsy specimensDriver gene mutationsPrognostic impactCancer patientsBiopsy specimensTargeted therapyOncologic practiceAccurate subclassificationIHC biomarkersImmunohistochemical markersPatient careAccurate diagnosisImmunotherapyTherapyCancerSubclassificationCritical roleCurrent insight in the localized insulin-derived amyloidosis (LIDA): clinico-pathological characteristics and differential diagnosis
Ansari AM, Osmani L, Matsangos AE, Li QK. Current insight in the localized insulin-derived amyloidosis (LIDA): clinico-pathological characteristics and differential diagnosis. Pathology - Research And Practice 2017, 213: 1237-1241. PMID: 28935176, DOI: 10.1016/j.prp.2017.08.013.Peer-Reviewed Original ResearchConceptsInsulin-derived amyloidosisSystemic amyloidosisDiabetic patientsGlycemic controlDifferential diagnosisAccurate diagnosisAggressive systemic therapyBlood glycemic controlCommon side effectsCase series studyClinico-pathological characteristicsNon-surgical approachSubcutaneous insulin injectionsPrimary cutaneous amyloidosisAnti-insulin antibodiesAutonomic neuropathyInsulin requirementsClinical suspicionKey diagnostic featuresRare complicationSystemic therapySurgical excisionSurgical interventionCase reportInsulin injections